HomeCategory news

Stuart Therapeutics Announces Important Additions to the Company’s Intellectual Property Portfolio

Stuart Therapeutics Announces Important Additions to the Company’s Intellectual Property Portfolio  STUART, Fla., July 22, 2022 /PRNewswire/ — Stuart Therapeutics, Inc. (Stuart), a clinical stage company developing advanced ophthalmic therapeutics, announced today that the United States Patent and Trademark office has issued a Notice of Allowance in each of two patent applications associated with the...

Stuart Therapeutics Announces Successful Outcome from Type C Meeting with FDA

STUART, Fla., July 18, 2022 /PRNewswire/ — Stuart Therapeutics, Inc. (Stuart), a clinical stage company headquartered in Stuart, Florida that is developing advanced ophthalmic therapeutics, announced today the results of its Type C Guidance meeting with the U.S. Food and Drug Administration (FDA) regarding the continued development plan for ST-100, Stuart’s first drug candidate for the...

Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye Candidate ST-100

Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye Candidate ST-100   – Achieved FDA Pre-Approved Single Primary Endpoint After 28 Days of Administration – Improvement in Total Ocular Discomfort after 14 Days   STUART, Fla., Jan. 3, 2022 /PRNewswire/ — Stuart Therapeutics, Inc. (STUART), a clinical stage, innovative ophthalmic...

Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease

Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease STUART, Fla., Sept. 8, 2021 /PRNewswire/ — Stuart Therapeutics, Inc. (“Stuart“), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced that it has completed patient enrollment in its Phase 2...

Stuart Therapeutics Completes its $11M Series A Round, led by InFocus Capital Partners, WARF and MiMo Capital

Stuart Therapeutics Completes its $11M Series A Round, led by InFocus Capital Partners, WARF and MiMo Capital Stuart Therapeutics, Inc. (“Stuart”), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced the completion of an $11 million Series A round of capital investment. The round was led...

Stuart Therapeutics Wins the AdvanSE Life Sciences Conference PitchRounds Competition

Stuart Therapeutics Wins the AdvanSE Life Sciences Conference PitchRounds Competition November 13th, 2020, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that the company’s presentation at the Southeast Life Sciences AdvanSE Life Sciences Conference was judged the winner of the PitchRounds Competition. The competition...

Stuart Therapeutics, Inc. Announces Presentation at ARVO 2020

Stuart Therapeutics, Inc. Announces Presentation at ARVO 2020 Stuart Therapeutics, Inc. (STUART), the leader in the application of collagen mimetic peptide (CMP) technology for ophthalmology, today announced that it has been selected as a presenter at the Association for Research of Vision and Ophthalmology (ARVO) 2020 Annual Meeting in Baltimore, Maryland, May 3rd through 7th...